Inhibin B Test

Your reproductive system sends a steady chemical signal into your bloodstream that reflects whether sperm production or egg development is on track. That signal is inhibin B, and when it drops, it often means the cells responsible for fertility are struggling, sometimes years before symptoms appear. For men, a falling level points to a problem inside the testes. For women, it can flag a shrinking pool of developing follicles.

What makes this marker especially useful is its directness. Standard hormone panels measure the brain's commands to the reproductive organs (FSH and LH), but inhibin B is the organ's reply. It tells you what the testes or ovaries are actually doing, not just what the brain is asking them to do. That distinction matters when you are trying to catch a problem early.

What Inhibin B Tells You

Inhibin B (the full name distinguishes it from a related hormone, inhibin A) is a protein hormone belonging to a large family of signaling molecules (the TGF-beta superfamily). It is made up of two linked protein chains. In men, it is produced primarily by Sertoli cells, the support cells inside the testes that nurse developing sperm through every stage of maturation. In women, it comes from granulosa cells, the cells that surround and nourish eggs inside small, developing follicles.

The hormone works as a feedback signal to the pituitary gland in your brain. When your gonads are functioning well and making enough inhibin B, it dials down the brain's release of FSH (follicle-stimulating hormone). When gonadal function falters and inhibin B drops, the brain responds by ramping up FSH. This is why a low inhibin B paired with a high FSH is such a clear signal of reproductive trouble.

Male Infertility

In men, inhibin B is the single best blood marker for active sperm production. In a study of 218 subfertile men, inhibin B alone achieved 95% diagnostic accuracy for distinguishing functioning spermatogenesis from impaired sperm production, compared to only 80% for FSH on its own. A separate study of 2,448 men found that the inhibin B-to-FSH ratio correctly classified normal versus abnormal semen quality 99.1% of the time, outperforming either marker alone.

For men with no sperm in their ejaculate (a condition called azoospermia), this marker can help predict whether sperm might still be found through a testicular biopsy. In a large study of over 30,000 Chinese men, a level above roughly 78 pg/mL predicted successful sperm retrieval with 59% sensitivity and 92% specificity. The ratio of inhibin B to FSH performed even better, correctly identifying candidates for sperm retrieval with 96% specificity.

Several conditions drive inhibin B to very low or undetectable levels in men. Klinefelter syndrome (a genetic condition where men carry an extra X chromosome) causes levels to fall off steeply during puberty. Another condition called congenital hypogonadotropic hypogonadism, where the brain never properly signals the testes, also produces low readings. A meta-analysis of 349 patients across seven studies found that inhibin B distinguished this condition from a temporary growth delay with 92% sensitivity and 92% specificity.

Ovarian Reserve in Women

In women, inhibin B reflects the pool of small, actively developing follicles in the ovaries. As this pool shrinks with age, inhibin B declines, and research shows this decline can begin before FSH starts rising. One study documented that women with diminishing ovarian reserve showed falling inhibin B levels while their day-3 FSH was still within the normal range.

However, a large study published in JAMA found that among 750 women aged 30 to 44 attempting to conceive naturally, inhibin B levels were not associated with the probability of conception. This is a key distinction: the marker reflects follicle quantity, not the ability to become pregnant on a given cycle. For this reason, the American Society for Reproductive Medicine does not recommend inhibin B for routine ovarian reserve testing, noting that AMH (anti-Mullerian hormone) is more reliable because it can be measured on any day of the menstrual cycle, while inhibin B must be drawn during the early follicular phase.

Granulosa Cell Tumors

One area where inhibin B shows exceptional clinical value is in detecting and monitoring granulosa cell tumors, a type of ovarian cancer that arises from the same cells that produce inhibin B. Studies report that 85% to 89% of these tumors produce measurably elevated inhibin B, with 100% specificity, meaning a positive result virtually confirms the diagnosis. Even more valuable for surveillance: elevated inhibin B can signal tumor recurrence a median of 11 months before any clinical signs appear.

When combined with AMH, the two markers together achieved 100% sensitivity and 93% specificity for distinguishing granulosa cell tumors from endometriomas, a common type of benign ovarian cyst. Standard ovarian cancer markers like CA-125 often miss these tumors entirely because they arise from a different cell type than the more common epithelial ovarian cancers.

Reference Ranges

Inhibin B levels vary dramatically by sex, age, and even which lab runs the test. Assays are not standardized across platforms, so the most meaningful comparisons are always between your own results drawn from the same lab over time. The values below, drawn from published population studies, provide general orientation.

Adult Men

In men, levels gradually decline after age 40, though the correlation with age is modest. Body weight has a more meaningful impact: each unit increase in BMI is associated with lower levels, and the effect becomes more pronounced above a BMI of approximately 31.

Adult Women

In women, levels fluctuate across the menstrual cycle (higher during the follicular phase, lower during the luteal phase) and drop substantially after age 40, eventually becoming undetectable at menopause. Oral contraceptives significantly suppress levels. Because of this variability, the ASRM considers inhibin B less reliable than AMH for clinical decision-making in women.

When Results Can Be Misleading

Body weight is the most common confounder. In women, a study of over 8,300 patients found that each 1 kg/m-squared increase in BMI was associated with a 3.59% reduction in inhibin B. Overweight and obese women showed reductions of roughly 19% and 35%, respectively. In men, the inverse relationship with BMI becomes more pronounced above a threshold of about 31 kg/m-squared. If your weight has changed significantly, your inhibin B may shift for reasons unrelated to actual gonadal health.

Inflammation can also push levels down. A study in reproductive-aged women found that a 20% increase in C-reactive protein was associated with a small but measurable decrease in inhibin B. Acute illness or chronic inflammatory conditions could suppress your reading without reflecting true reproductive decline.

Oral contraceptives substantially suppress inhibin B in women, reflecting the suppression of follicular development that is their intended mechanism. If you are using hormonal contraception, your result will not reflect your underlying ovarian reserve. Testosterone therapy in men partially reduces inhibin B but does not suppress it completely.

Inhibin B shows mild diurnal variation in men, tracking a similar pattern to testosterone. Drawing blood at a consistent time of day matters for serial comparisons. Acute heavy exercise does not appear to significantly shift levels in the short term.

Tracking Your Trend

A single inhibin B reading is useful for context, but the real value comes from tracking your number over time. In men, the intra-individual variation is approximately 10%, meaning most of the bounce between readings comes from the test itself, not from your body changing day to day. This makes it a reliable marker for serial monitoring: any change beyond about 20% to 30% in men likely reflects a genuine biological shift.

For women, timing matters. Readings should be taken during the early follicular phase (cycle days 2 through 5) for consistency. Because levels fluctuate meaningfully across the cycle, comparing a follicular-phase draw to a luteal-phase draw would be misleading.

If you are starting gonadotropin therapy for hypogonadotropic hypogonadism, tracking inhibin B every three to six months gives you a direct measure of whether Sertoli cells are responding to treatment. If you are a woman monitoring ovarian reserve over time, an annual early-follicular draw alongside AMH and FSH provides the clearest trajectory. Establishing a baseline now and comparing future readings within the same lab is far more informative than trying to interpret any single number against population averages.